Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer

NCT05416983 | Completed

• 2 other identifiers: 21-013359NCI-2022-01685
• Study Type: observational
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

This study observes conversations between non-small cell lung cancer patients and their doctors to support the development of a decision aid that can be used to inform discussions about treatment options for after surgery. Patients who have undergone surgery for their non-small cell lung cancer may have the option of completing additional treatment. Patients contemplating this additional treatment have been shown to be most satisfied with their choice if they perceive an effort by their doctor to share decision making. Shared decision making tools can help doctors guide conversations, offer tailored recommendations, and support deliberation on whether or not to pursue treatment. This study develops a shared decision making tool for patients with surgically removed non-small cell lung cancer contemplating additional treatment.

Conditions

Lung Non-Small Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Development of decision aid

  Up to study completion, up to 2 years

Study Arms (1)

Observational (discussion)

Patient and clinician discussions are observed to support refinement of a decision aid. Clinicians may use a prototype of the decision aid in discussions with their patients and may complete a questionnaire.

Procedure: Discussion; Other: Questionnaire Administration

Interventions

Discussion PROCEDURE

Attend discussion

Observational (discussion)

Questionnaire Administration OTHER

Complete questionnaire

Observational (discussion)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with resected non-small cell lung cancer, clinicians, and PAG members.

You may qualify if:

• PATIENTS:
• Adults \>= 18 years with biopsy proven resected non-small cell lung cancer (NSCLC)
• Appointments to discuss adjuvant treatment of resected NSCLC
• CLINICIANS:
• Clinicians who meet with patients to discuss adjuvant treatment of resected NSCLC
• PAG MEMBERS:
• Adults \>= 18 years
• Member of the Knowledge and Evaluation Research (KER) Unit Patient Advisory Group (PAG)

You may not qualify if:

• PATIENTS
• Major barriers to providing informed consent (i.e., dementia, severe hearing or visual impairment)

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

• Mayo Clinic Clinical Trials

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Konstantinos Leventakos, M.D.

  Mayo Clinic in Rochester

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2022
• First Posted: June 14, 2022
• Study Start: February 17, 2022
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2023
• Last Updated: October 30, 2025

Record last verified: 2025-10

Locations

US (1)